Related references
Note: Only part of the references are listed.Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
Michael E. Abram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy
Frauke Christ et al.
VIROLOGY (2013)
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
Carolina Garrido et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo
Signe Fransen et al.
JOURNAL OF VIROLOGY (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus et al.
LANCET (2012)
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
Mark A. Winters et al.
PLOS ONE (2012)
The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
Matthias Goette
CURRENT OPINION IN VIROLOGY (2012)
Switching between raltegravir resistance pathways analyzed by deep sequencing
Rithun Mukherjee et al.
AIDS (2011)
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
Mathieu Metifiot et al.
AIDS (2011)
Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A
S. Reigadas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Jose-Luis Blanco et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo
Olivier Delelis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
Daniel da Silva et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
Filippo Canducci et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Retroviral intasome assembly and inhibition of DNA strand transfer
Stephen Hare et al.
NATURE (2010)
The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
Sandrine Reigadas et al.
PLOS ONE (2010)
Raltegravir: The First HIV Type 1 Integrase Inhibitor
Charles Hicks et al.
CLINICAL INFECTIOUS DISEASES (2009)
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
Isabelle Malet et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Signe Fransen et al.
JOURNAL OF VIROLOGY (2009)
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
Olivier Delelis et al.
NUCLEIC ACIDS RESEARCH (2009)
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
Isabelle Malet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
Olivia Goethals et al.
JOURNAL OF VIROLOGY (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Styrylquinolines, integrase inhibitors acting prior to integration:: a new mechanism of action for anti-integrase agents
S Bonnenfant et al.
JOURNAL OF VIROLOGY (2004)
New class of HIV integrase inhibitors that block viral replication in cell culture
C Pannecouque et al.
CURRENT BIOLOGY (2002)
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
DJ Hazuda et al.
SCIENCE (2000)
Share Paper
